Relapsing Forms of Multiple Sclerosis: Clinical Trials

2 trials for Relapsing Forms of Multiple Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Completed 2

Follow Relapsing Forms of Multiple Sclerosis: new trials by email Literature Review of Relapsing Forms of Multiple Sclerosis trials Research Report on Relapsing Forms of Multiple Sclerosis

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
Diroximel fumarate - Relapsing Forms of Multiple Sclerosis
Phase 3CompletedBiogen1362021-11-182025-10-24
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
Fingolimod - Relapsing Forms of Multiple Sclerosis
Phase 3CompletedNovartis Pharmaceuticals41252010-09-132021-04-21

Narrower conditions

Multiple Sclerosis (1)

Broader conditions

Autoimmune Diseases (1)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Demyelinating Autoimmune Diseases, CNS (1)  ·  Demyelinating Diseases (1)  ·  Immune System Diseases (1)  ·  Nervous System Diseases (1)

Interventions

Fingolimod Hydrochloride (1)  ·  diroximel fumarate (1)

Sponsors

Biogen (1)  ·  Novartis Pharmaceuticals (1)

Countries

Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  China (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Egypt (1)  ·  Estonia (1)  ·  Finland (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)

Results publications

PMID 31598139